Clinical Trials

50 enrolled

Colonic Neoplasms, Rectal Neoplasms

NCT06258525 2026-03-18

SAMe in Prevention of Oxaliplatin-associated Liver Injury

Classical hematologyGastrointestinal

30 enrolled

Hepatic Veno-Occlusive Disease, Colorectal Neoplasms, Chemical and Drug Induced Liver Injury

NCT06561360 2026-03-18

A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)

Other hematologic neoplasm

86 enrolled

Leukemia, Hairy Cell

NCT06658405 2026-03-18

HPV2

85 enrolled

Tumor-Agnostic

Neoplasms

NCT07010497 2026-03-18

IAPETUS

33 enrolled

Carcinoma, Hepatocellular

NCT07209449 2026-03-18

A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer

75 enrolled

Gynecologic

Recurrence, Endometrial Neoplasms

NCT07283705 2026-03-18

A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer

Phase 2 Suspended

60 enrolled

Phase 2 Study

NCT07472933 2026-03-18

Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies

44 enrolled

Cancer of Biliary Duct

NCT07479628 2026-03-18

Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma

31 enrolled

Thoracic

Thymoma

NCT07480733 2026-03-18

A Phase II Clinical Study Evaluating the Safety, Tolerability,Pharmacokinetics, and Preliminary Efficacy of JS212 andJS213 as Monotherapy and in Combination in Patients Withadvanced Malignant Solid Tumors

480 enrolled

Other solid neoplasm

Advanced Malignant Solid Tumors

NCT07480850 2026-03-18

Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma

40 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT07480863 2026-03-18

Treatment of BTKi+Hi-CVP Regimen for Previously Untreated MZL

65 enrolled

Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT01612351 2026-03-17

Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery

Phase 2 Completed

40 enrolled 20 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT02114229 2026-03-17

SJATRT

125 enrolled

Rhabdoid Tumor

NCT02482376 2026-03-17

Preoperative Single-Fraction Radiotherapy in Early Stage Breast Cancer

110 enrolled 18 charts

Breast Neoplasms

NCT02818920 2026-03-17

TOP 1501

Phase 2 Completed

35 enrolled 11 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03462342 2026-03-17

CAPRI

Phase 2 Completed

123 enrolled

High Grade Serous Carcinoma

NCT03590171 2026-03-17

International Study for Treatment of High Risk Childhood Relapsed ALL 2010

LymphoidOther hematologic neoplasm

250 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05023655 2026-03-17

Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation

Phase 2 Terminated

20 enrolled

Other solid neoplasm

Solid Tumor

NCT05436561 2026-03-17

Reduced MBF Regimen for Patients >=55 Years With Myeloid Malignancies

61 enrolled

Disease-free Survival

NCT05478512 2026-03-17

VIS

LymphoidOther hematologic neoplasm

78 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05656131 2026-03-17

Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer

Phase 2 Suspended

80 enrolled

Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer

NCT05746208 2026-03-17

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

29 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT06353022 2026-03-17

IFm2022-01

103 enrolled

Plasma cell

Multiple Myeloma

NCT06649331 2026-03-17

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

160 enrolled

Phase 2 Enrolling by invitation

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06650748 2026-03-17

NeoMARS

100 enrolled

Breast Neoplasms

NCT06807164 2026-03-17

SerCaBot

123 enrolled

Agnosia, Breast Neoplasms

NCT06898970 2026-03-17

Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma

18 enrolled

Sarcoma

Hemangiosarcoma

NCT07021989 2026-03-17

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

38 enrolled

Lymphoid

Hodgkin Disease

NCT07092514 2026-03-17

Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)

34 enrolled

Head & Neck

Thyroid Neoplasms

NCT07111507 2026-03-17

A Study of Tarlatamab for People With Prostate Cancer

32 enrolled

Prostatic Neoplasms

NCT07282483 2026-03-17

Traditional Chinese Medicine Oral Liquids and Mouthwashes for Radiation-induced Oral Mucositis in Head and Neck Cancer Patients

118 enrolled

Other

Radiation-induced Oral Mucositis

NCT07322263 2026-03-17

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

174 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT07362979 2026-03-17

Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma

243 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT07474064 2026-03-17

Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC

146 enrolled

Muscle Invasive Bladder Cancer (MIBC)

NCT07476001 2026-03-17

Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC

12 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT07476677 2026-03-17

ANDARP

60 enrolled

Prostatic Neoplasms

NCT07476794 2026-03-17

TEMPO

118 enrolled

CNS

Glioblastoma

NCT07477457 2026-03-17

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

45 enrolled

Sarcoma

Neoplasm Metastasis, Osteosarcoma

NCT07477548 2026-03-17

A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies